ORIC Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
107
- Stock Symbol
-
ORIC
- Share Price
-
$9.62
- (As of Friday Closing)
ORIC Pharmaceuticals General Information
Description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Contact Information
Website
www.oricpharma.comCorporate Office
- 240 East Grand Avenue
- 2nd Floor
- South San Francisco, CA 94080
- United States
Corporate Office
- 240 East Grand Avenue
- 2nd Floor
- South San Francisco, CA 94080
- United States
ORIC Pharmaceuticals Timeline
ORIC Pharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.62 | $9.48 | $5.27 - $16.65 | $679M | 70.5M | 555K | -$1.77 |
ORIC Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 162,673 | 277,309 | 73,750 | 291,192 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (109,729) | (99,665) | (88,156) | (77,956) |
| Net Income | (110,782) | (100,697) | (89,122) | (78,715) |
| Total Assets | 328,906 | 252,007 | 247,178 | 298,642 |
| Total Debt | 2,770 | 2,752 | 2,659 | 1,926 |
ORIC Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ORIC Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
ORIC Pharmaceuticals Comparisons
Industry
Financing
Details
000000
000000
ORIC Pharmaceuticals Competitors (90)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. | |
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| Iovance Biotherapeutics | Corporation | San Carlos, CA | 000 | 00000 | 00000000 | 00000 |
| Loxo Oncology | Formerly VC-backed | Stamford, CT | 00 | 00000 | 000000&0 | 00000 |
ORIC Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ORIC Pharmaceuticals Patents
ORIC Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4404932-A1 | Prc2 inhibitors for use in treating blood disorders | Pending | 24-Sep-2021 | 000000000 | |
| US-20230365537-A1 | Polo like kinase 4 inhibitors | Active | 11-May-2021 | 0000000000 | |
| CA-3217983-A1 | Polo like kinase 4 inhibitors | Pending | 11-May-2021 | 0000000000 | |
| AU-2022272184-A1 | Polo like kinase 4 inhibitors | Pending | 11-May-2021 | 0000000000 | |
| US-20240124426-A1 | Polo like kinase 4 inhibitors | Pending | 11-May-2021 | C07D403/14 |
ORIC Pharmaceuticals Executive Team (16)
| Name | Title | Board Seat |
|---|---|---|
| Jacob Chacko MD | President, Chief Executive Officer & Board Member | |
| Dominic Piscitelli | Chief Financial Officer | |
| Charles Sawyers MD | Co-Founder & Scientific Advisory Board | |
| Scott Lowe Ph.D | Co-Founder & Scientific Advisory Board | |
| Richard Heyman Ph.D | Co-Founder, Chairman & Scientific Advisory Board |
ORIC Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Angie You Ph.D | Self | Board Member | 000 0000 |
| Jacob Chacko MD | ORIC Pharmaceuticals | President, Chief Executive Officer & Board Member | 000 0000 |
| Leo Guthart | Self | Board Member | 000 0000 |
| Lori Kunkel MD | Self | Board Member | 000 0000 |
| Mardi Dier | Self | Board Member | 000 0000 |
ORIC Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ORIC Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ORIC Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated January, 24, 2024
31.91 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
ORIC Pharmaceuticals FAQs
-
When was ORIC Pharmaceuticals founded?
ORIC Pharmaceuticals was founded in 2014.
-
Who is the founder of ORIC Pharmaceuticals?
Charles Sawyers MD, Scott Lowe Ph.D, and Richard Heyman Ph.D are the founders of ORIC Pharmaceuticals.
-
Who is the CEO of ORIC Pharmaceuticals?
Jacob Chacko MD is the CEO of ORIC Pharmaceuticals.
-
Where is ORIC Pharmaceuticals headquartered?
ORIC Pharmaceuticals is headquartered in South San Francisco, CA.
-
What is the size of ORIC Pharmaceuticals?
ORIC Pharmaceuticals has 107 total employees.
-
What industry is ORIC Pharmaceuticals in?
ORIC Pharmaceuticals’s primary industry is Drug Discovery.
-
Is ORIC Pharmaceuticals a private or public company?
ORIC Pharmaceuticals is a Public company.
-
What is ORIC Pharmaceuticals’s stock symbol?
The ticker symbol for ORIC Pharmaceuticals is ORIC.
-
What is the current stock price of ORIC Pharmaceuticals?
As of 06-Sep-2024 the stock price of ORIC Pharmaceuticals is $9.62.
-
What is the current market cap of ORIC Pharmaceuticals?
The current market capitalization of ORIC Pharmaceuticals is $679M.
-
Who are ORIC Pharmaceuticals’s competitors?
ImmunityBio, Sorrento Therapeutics, CytomX Therapeutics, Iovance Biotherapeutics, and Loxo Oncology are some of the 90 competitors of ORIC Pharmaceuticals.
-
What is ORIC Pharmaceuticals’s annual earnings per share (EPS)?
ORIC Pharmaceuticals’s EPS for 12 months was -$1.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
